Condition: Acute Lymphoblastic Leukemia · ALL, Childhood · ALL · Sponsor: University of Chicago
This study will test if adding ruxolitinib to standard multi-drug chemotherapy regimen will be safe and tolerated in adolescents and young adults with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL).
This description comes directly from the study's public registry record.
Clinical Trials Office · 1-855-702-8222 · cancerclinicaltrials@bsd.uchicago.edu
Always discuss trial participation with your own doctor first.
| University of Chicago Medical Center | Chicago, Illinois, United States | Recruiting |
| The University of Texas Southwestern Medical Center | Dallas, Texas, United States | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03571321